Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Opioid Abuse: The Limits Of Industry’s Response

Executive Summary

PhRMA is endorsing dispensing limits on opioids and pledging to support a public/private partnership to develop new treatments and alternatives. But members of a Presidential Commission didn’t seem impressed.

You may also be interested in...



Mandatory Provider Training For Opioids Embraced By PhRMA

Trade association members also commit tens of millions of dollars to set up addiction prevention programs and create new health care tools.

White House Opioid Report Urges Better Access To Overdose Treatment; Mandatory Prescriber Education

Pricing of anti-addiction therapies could come under more pressure from HHS if Trump Administration accepts White House commission recommendation to declare public health emergency on opioid crisis.

The Aspirin Test For AI?

US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS121757

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel